,i #aaith ,,congress #b;d ,session ,h4 ,r4 #ajjhh ,,in ,,the ,,house ,,of ,,representatives ,august #ac1 #bjbf,mrs4 ,foushee introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce ,a ,,bill ,to direct the ,secretary of ,health and ,human ,services1 acting through the ,commissioner of ,food and ,drugs1 to conduct a study to assess the potential for expanding the safe and effective use of reprocessed single-use devices1 and for other purposes4 #a4 ,reprocessing of single-use devices 7a7 ,study ,the ,secretary of ,health and ,human ,services1 acting through the ,commissioner of ,food and ,drugs 7in this section referred to as the ,secretary71 shall conduct a study to assess the potential for expanding the safe and effective use of reprocessed single-use devices4 7b7 ,primary criteria ,in conducting the study under subsection 7a71 the ,secretary shall ensure that patient safety and infection prevention are the primary criteria used in examining the potential for reprocessing single-use devices1 with stratification by risk category and clinical use4 7c7 ,focus on third-,party reprocessors ,in conducting the study under subsection 7a71 the ,secretary shall evaluate opportunities for1 and barriers to1 the expanded use of qualified third-party reprocessors4 7d7 ,contents ,in conducting the study under subsection 7a71 the ,secretary shall examine1 at a minimum-- 7#a7 existing pathways of the ,food and ,drug ,administration for the reprocessing of single-use devices1 including instances in which current rules are sufficient and instances in which barriers exist2 7#b7 the role of third-party reprocessors of single-use devices versus in-house hospital reprocessing2 7#c7 the operational feasibility of reprocessing single-use devices1 including sterile processing capacity1 staffing1 equipment1 chain of custody1 tracking1 and quality assurance2 7#d7 the financial and environmental return of reprocessing single-use devices1 taking into consideration waste reduction1 cost savings1 and any added labor1 capital1 or compliance burden2 and 7#e7 issues related to liability and accountability if a reprocessed single-use device fails or contributes to patient harm4 7e7 ,considerations ,in conducting the study under subsection 7a71 the ,secretary shall consider1 with respect to the reprocessing of single-use devices-- 7#a7 clinical outcomes and device performance2 7#b7 validated reprocessing-cycle limits2 7#c7 collection and transportation logistics2 7#d7 the percentage of collected devices that can be reprocessed2 7#e7 contractual or technical barriers2 and 7#f7 full lifecycle financial and environmental impact4 7f7 ,consultation ,in conducting the study under subsection 7a71 the ,secretary shall seek input from-- 7#a7 non-,federal entities1 including hospitals1 supply chain leaders1 infection prevention organizations1 sterile processing organizations1 clinicians1 and appropriate industry representatives2 and 7#b7 ,federal entities1 including the ,food and ,drug ,administration1 the ,centers for ,disease ,control and ,prevention1 and the ,centers for ,medicare ,medicaid ,services4 7g7 ,definitions ,in this section1 the terms device1 reprocessed1 and single-use device have the meanings given such terms in section #bja of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cba74 7h7 ,report to ,congress ,not later than #a year after the date of enactment of this ,act1 the ,secretary shall transmit to ,congress a report on the results of the study1 including-- 7#a7 a listing of single-use devices that the ,secretary determines have the potential for reprocessing1 including an identification of-- 7,a7 devices currently legally marketed for reprocessing2 7,b7 devices for which reprocessing is supported by sufficient evidence2 and 7,c7 devices for which reprocessing requires further research2 and 7#b7 recommendations for programs and activities to provide for such reprocessing1 including the use of-- 7,a7 qualified third-party reprocessors2 7,b7 appropriate cleaning and sterilization technology2 7,c7 quality assurance and tracking systems2 and 7,d7 infection prevention controls4